Vancouver, British Columbia – Motic, a leading provider of digital pathology solutions, today announced that the MoticEasyScan product line of Whole Slide Scanners obtained a Health Canada Class II Medical Device License. MoticEasyScan systems are now certified for Clinical use in Canada, introducing, for the first time, high-quality and affordable solutions to facilitate Digital Pathology adoption in Canada. Health Canada Class II certification will enable pathologists in Canada to use the MoticEasyScan scanners and software as diagnostic tools to scan, share and use whole-slide images for primary diagnosis.

The ability for digital pathology to help fight cancer in lower income countries is both one of the most recognized potentials of the technology, and also one of its least-often fulfilled. Motic’s goals for its new telepathology platform is to help affordably connect regional front-line hospitals with global medical professionals to advance healthcare and scientific discovery.

In this work, a team conducts an investigation of the expression of the CREB1 gene in ovarian cancer by deeply excavating the gene information in multiple databases and the mechanism.

Featured in April 2021’s edition of The Pathologist, various images scanned using a MoticEasyScan Pro were included in the “Picture Perfect Pathology,” editorial.

During this tutorial, Dr. Kabeer Shah speaks to the specific clinical use cases where whole-slide imaging and digital pathology improve the efficiency of his practice, and how clinicians in organizations, both big and small, can better understand how digital pathology can contribute to their practice.

Whole-slide imaging (WSI) digital pathology represents a viable option for improving efficiencies in clinical workflows; however, this doesn’t come without complications. Unless hospital systems and labs fully understand their own use cases and how digital pathology would tangibly benefit them, convincing administrators and colleagues to invest in this technology can prove to be difficult.

In this work, a team conducts an investigation to experimentally demonstrate the therapeutic benefits of MLA-assisted fractional PTT on colorectal cancer, in comparison to flat fiber-based PTT.

Motic and its partners, Dr. Böcking and the BC Cancer Agency, implemented digital pathology using DNA-ploidy analysis to automate and scale cervical cancer screening in underserved areas in China.

Published in Pathology – Research and Practice, this article evaluates the current state of digital pathology for clinical, research, and education use and looks forward to future challenges and developments.

In this work, a team observed the interplay between TFPI and FV in regulating hemostasis and vascular development during embryogenesis.